Silibinin Suppresses Tumor Cell-Intrinsic Resistance to Nintedanib and Enhances Its Clinical Activity in Lung Cancer
Authors:
- Joaquim Bosch-BarreraJoaquim Bosch-Barrera
- Sara VerduraSVSara Verdura
- José Carlos RuffinelliJRJosé Carlos Ruffinelli
- Enric CarcerenyECEnric Carcereny
- Elia SaisESElia Sais
- Elisabet CuyàsECElisabet Cuyàs
- Ramon PalmeroRPRamon Palmero
- Eugeni Lopez-BonetELEugeni Lopez-Bonet
- Alejandro Hernández-MartínezAHAlejandro Hernández-Martínez
- Gloria OliverasGOGloria Oliveras
- Maria BuxóMBMaria Buxó
- Angel IzquierdoAIAngel Izquierdo
Open Access
Abstract
The anti-angiogenic agent nintedanib has been shown to prolong overall and progression-free survival in patients with advanced non-small-cell lung cancer (NSCLC) who progress after first-line platinum-based chemotherapy and second-line immunotherapy. Here, we explored the molecular basis and the clinical benefit of incorporating the STAT3 inhibitor silibinin—a flavonolignan extracted from milk thistle—into nintedanib-based schedules in advanced NSCLC. First, we assessed the nature of the tumoricidal interaction between nintedanib and silibinin and the underlying relevance of STAT3 activation in a panel of human NSCLC cell lines. NSCLC cells with poorer cytotoxic responses to nintedanib exhibited a persistent, nintedanib-unresponsive activated STAT3 state, and deactivation by co-treatment with silibinin promoted synergistic cytotoxicity. Second, we tested whether silibinin could impact the lysosomal sequestration of nintedanib, a lung cancer cell-intrinsic mechanism of nintedanib resistance. Silibinin partially, but significantly, reduced the massive lysosomal entrapment of nintedanib occurring in nintedanib-refractory NSCLC cells, augmenting the ability of nintedanib to reach its intracellular targets. Third, we conducted a retrospective, observational multicenter study to determine the efficacy of incorporating an oral nutraceutical product containing silibinin in patients with NSCLC receiving a nintedanib/docetaxel combination in second- and further-line settings (n = 59). Overall response rate, defined as the combined rates of complete and partial responses, was significantly higher in the study cohort receiving silibinin supplementation (55%) than in the control cohort (22%, p = 0.011). Silibinin therapy was associated with a significantly longer time to treatment failure in multivariate analysis (hazard ratio 0.43, p = 0.013), despite the lack of overall survival benefit (hazard ratio 0.63, p = 0.190). Molecular mechanisms dictating the cancer cell-intrinsic responsiveness to nintedanib, such as STAT3 activation and lysosomal trapping, are amenable to pharmacological intervention with silibinin. A prospective, powered clinical trial is warranted to confirm the clinical relevance of these findings in patients with advanced NSCLC.Keywords
Funding Information
- Ministerio de Ciencia e Innovación (SAF2016-80639-P, PID2019-104055GB-I00)
- Departament de Salut, Generalitat de Catalunya (SLT006/17/114)
- Fundació la Marató de TV3 (201906)
This publication has 86 references indexed in Scilit:
- Exhaled breath condensate in intubated neonates- a window into the lung’s glutathione statusRespiratory Research, 2014
- IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutationsScientific Reports, 2013
- Anticancer Targets in the Glycolytic Metabolism of Tumors: A Comprehensive ReviewFrontiers in Pharmacology, 2011
- The iron-chelating potential of silybin in patients with hereditary haemochromatosisEuropean Journal of Clinical Nutrition, 2010
- Signal Transducers and Activators of Transcription-3 Binding to the Fibroblast Growth Factor Receptor Is Activated by Receptor AmplificationCancer Research, 2010
- Reciprocal Regulation of c-Src and STAT3 in Non-Small Cell Lung CancerClinical Cancer Research, 2009
- Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in miceJournal of Clinical Investigation, 2008
- Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination StudiesPharmacological Reviews, 2006
- Complete isolation and characterization of silybins and isosilybins from milk thistle (Silybum marianum)Electronic supplementary information (ESI) available: HPLC chromatograms of isolates and extracts. See http://www.rsc.org/suppdata/ob/b3/b300099k/Organic & Biomolecular Chemistry, 2003
- Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cellsOncogene, 2001